Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy

Figures & data

Table 1 Patients’ characteristics

Prognostic factor	TNBC patient grouping based on PORT treatment		TNBC patients n=111 (100%)	Non-TNBC patients cross-matching (n=111)a
	PORT n=70 (63%)	Non-PORT n=41 (37%)
Age, years	54±7	68±13	63±7 (range 28–81)	60±11
Pathology type
IDC	63 (90%)	31 (76%)	94 (85%)	80 (72%)
ILC	5 (7%)	9 (22%)	14 (13%)	22 (20%)
Others	2 (3%)	1 (2%)	3 (2%)	9 (8%)
T stage
T1	20 (29%)	12 (29%)	32 (29%)	24 (22%)
T2	24 (34%)	18 (44%)	42 (38%)	50 (45%)
T3	17 (24%)	7 (17%)	24 (22%)	17 (15%)
T4	9 (13%)	4 (10%)	13 (11%)	20 (18%)
Lymph node status
N0	11 (16%)	18 (44%)	29 (26%)	28 (25%)
N1–3	14 (20%)	10 (24%)	24 (22%)	17 (15%)
N≥4	45 (64%)	13 (32%)	58 (52%)	66 (60%)
AJCC stage
I	8 (11%)	10 (24%)	18 (16%)	14 (12%)
II	9 (13%)	8 (20%)	17 (15%)	25 (23%)
III	53 (76%)	23 (56%)	76 (69%)	72 (65%)
Grade
1	10 (14%)	14 (34%)	24 (22%)	19 (17%)
2	33 (47%)	11 (27%)	44 (40%)	35 (32%)
3	27 (39%)	16 (39%)	43 (38%)	57 (51%)
Surgery
MRM	38 (54%)	29 (71%)	67 (60%)	67 (60%)
BCT	32 (46%)	12 (29%)	44 (40%)	44 (40%)
Chemotherapy
Neoadjuvant	35 (50%)	16 (39%)	51 (46%)	33 (30%)
Adjuvant	28 (40%)	20 (49%)	48 (43%)	43 (39%)
None	7 (10%)	5 (12%)	12 (11%)	7 (6%)
Hormonal	0	0	0	87 (78%)

Note:

a 83 received radiation and 28 did not receive radiation (matching mainly done based on surgical type and stage).

Abbreviations: AJCC, American Joint Committee on Cancer; BCT, breast-conserving treatment; IDC, invasive duct carcinoma; ILC, invasive lobular carcinoma; MRM, modified radical mastectomy; PORT, postoperative radiotherapy; TNBC, triple-negative breast cancer.

Figure 1 (A) Effect of PORT on LRFS in TNBC patients. (B) Effect of surgical type on LRFS in TNBC patients. (C) Effect of PORT on OS in TNBC patients. (D) Effect of surgical type on OS in TNBC patients.

Abbreviations: BCT, breast-conserving treatment; LRFS, local recurrence-free survival; MRM, modified radical mastectomy; OS, overall survival; PORT, postoperative radiotherapy; TNBC, triple-negative breast cancer.

Table 2 Five-year-LRFS and 5-year OS in TNBC

Prognostic factor	5-year LRFS (%)	P-value	5-year OS (%)	P-value
All patients
TNBC (111 patients)	88±6	0.8	54±8	0.04
Non-TNBC (111 patients)	90±11		72±10
TNBC patients
Radiation therapy
PORT	94±4	0.001	65±13	0.09
Non-PORT	82±7		51±6
Surgical treatment
MRM (67 patients)	85±5	0.2	43±7	0.11
BCT (44 patients)	90±8		57±10
Chemotherapy
Neoadjuvant (51 patients)	87±5	0.4	55±5	0.3
Adjuvant (48 patients)	86±6		58±4

Abbreviations: BCT, breast-conserving treatment; LRFS, local recurrence-free survival; MRM, modified radical mastectomy; OS, overall survival; PORT, postoperative radiotherapy; TNBC, triple-negative breast cancer.

Figure 2 (A) Cross-matching between TNBC patients and non-TNBC patients: LRFS difference. (B) OS difference between TNBC patients and non-TNBC patients.

Abbreviations: LRFS, local recurrence-free survival; OS, overall survival; PORT, postoperative radiotherapy; TNBC, triple-negative breast cancer.